Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640472 | 0.85 | TDP1 (0.69) | TDP1ABCG2MEN1KMT2ASIRT5 | |
| SCHEMBL6643674 | 0.85 | TDP1 (0.69) | TDP1ABCG2MEN1KMT2ASIRT5 | |
| SCHEMBL8595899 | 0.84 | TDP1 (0.74) | TDP1ABCG2MEN1KMT2ASIRT5 | |
| SCHEMBL6640992 | 0.84 | ALDH1A1 (0.47) | TDP1MEN1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL3148208 | 0.80 | TDP1 (1.00) | TDP1ABCG2MEN1KMT2ASIRT5 | |
| Hydrochloric Acid SCHEMBL11714021 | 0.77 | TDP1 (0.74) | TDP1ABCG2MEN1KMT2ASIRT5 | |
| SCHEMBL6640560 | 0.76 | TDP1 (0.58) | TDP1ABCG2MEN1KMT2APOLB | |
| SCHEMBL6640567 | 0.76 | TDP1 (0.58) | TDP1ABCG2MEN1KMT2APOLB | |
| SCHEMBL6640024 | 0.76 | HDAC3 (0.55) | SMN1; SMN2 | |
| SCHEMBL4245813 | 0.75 | TDP1 (0.64) | TDP1ABCG2MEN1KMT2ASIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | TDP1 1950/4885ABCG2 6/4885MEN1 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.